Background
Methods
Search strategy
Study selection
Data extraction
Results
Study (reference and country) | Cell type | ATRA treatment | miRNAs upregulated | miRNAs downregulated |
---|---|---|---|---|
Chen and Stallings (2007) [31] United States | SK-N-BE | 5 μmol/L for 5 days | 17; miR-330, miR-187, miR-331, miR-200c, miR-216, miR-150, miR-141, miR-200a, miR-326, miR-186, miR-30b, miR-137, miR-184, miR-129, let-7b, let-7a and miR-181a; most significant: miR-184 | 4; miR-323, miR-302a, miR-181b and miR-92; most significant miR-192 |
Laneve et al. (2007) [20] Italy | SK-N-BE | 10 μmol/L for 10 days | 14; miR-9, miR-124a, miR-125a, miR-125b, let-7a, let-7b, miR-7, miR-22, miR-23a, miR-24, miR-26a, miR-30a-5p, miR-100 and miR-103; most significant: miR-124a | – |
Evangelisti et al. (2009) [21] Italy | SH-SY5Y | 10 μmol/L for 6 days |
miR-128
| – |
Le et al. (2009) [32] United States | SH-SY5Y | 10 μmol/L for 5 days | 6; miR-7, miR-124a, miR-125b, miR-199a, miR-199a*, and miR-214; most significant: miR-199a* | – |
Beverigde et al. (2009) [33] Australia | SH-SY5Y | 10 μmol/L for 6 days | 12; miR-10a, miR-128a, miR-331, miR-124a, miR-409-5p, miR-210, miR-149, miR-9, miR-423, miR-483, miR-208 and miR-184; most significant: miR-10a. | 32; miR-301, miR-19a*, miR-520d*, miR-18a*, miR-106a*, miR-218, miR-20a, miR-137, miR-15b, miR-20b*, miR-25*, miR-130a, miR-29b, miR-19b*, miR-34a, let-7a, miR-195, miR-106b*, miR-199a, miR-92*, miR-138, miR-93*, miR-432, miR-519e, miR-101, miR-518f-526a, miR-21, miR-134, miR-98, miR-370, miR-525 and miR-91 (aka miR-17-5p); most significant: miR-301. |
Ragusa et al. (2010) [34] Italy | SK-N-BE | 10 μmol/L for 10 days | 3; miR-152, miR-200b and miR-338; most significant: miR-200b | – |
Meseguer et al. (2010) [35] Spain | SH-SY5Y | 1 μmol/L for 4 days | 26; miR-10a, miR-10b, miR-10b, miR-615-5p, miR-211, miR-212, miR-132, miR-22, miR-766, miR-135a, miR-148b*, miR-877, miR-184, miR-135b, miR-30e, miR-214, miR-92b, mir-99b, miR-628-3p, miR-27b, miR-335, miR-25, miR-30a, miR-610, miR-331, 3p, miR-149; most significant: miR-10a and miR-10b | 16; miR-490-3p, miR-154, miR-26a-2, miR-296-3p, miR-422a, miR-486-3p, miR-378, miR-411, miR-543, miR-801, miR-873, miR-107, miR-744, miR-139-3p, miR-487b and miR-106a; most significant: miR-490-3p |
Das et al. (2010) [36] Ireland | SK-N-BE | 5 μmol/L for 7 days | 17; miR-132, miR-10a, miR-10b, miR-210, miR-192, miR-184, miR-146b, miR-152, miR-126, miR-615, miR-21, miR-203, miR-214, miR-24, miR-196a, miR-191 and let-7e; most significant: miR-132 | 17; miR-409-5p, miR-656, miR-299-5p, miR-485-5p, miR-424, miR-127, miR-323, miR-339, miR-576, miR-432, miR-433, miR-7, miR-30e-5p, miR-485-3p, miR-379, miR-134 and miR-487b; most significant: miR-432 |
Das et al. (2012) [37] Ireland | SK-N-BE and SHSY-5Y | 5 μmol/L for 7 days |
miR-340
|
–
|
Chen et al. (2010) [38] United Kingdom | SH-SY5Y | 10 μmol/L for 48 h | 6; miR-132, miR-16, miR-27a, miR-27b, miR-214, and miR-197; most significant: miR-132. | 6; miR-133a, miR-508-3p, miR-7, miR-1, miR-205, and miR-20; most significant: miR-20b |
Foley et al. (2011) [39] Ireland | SK-N-BE, SHSY-5Y and LAN-5 | 5 μmol/L for 7 days | 30; miR-132, miR-10a, miR-10b, miR-210, miR-192, miR-184, miR-146b, miR-152, miR-126, miR-615, miR-21, miR-203, miR-214, miR-24, miR-196a, miR-191, miR-7e, miR-28, miR-95, miR-26b, miR-26a, miR-199a, miR-374, miR-340, miR-125b, miR-125a, miR-7 g, miR-425-5p, miR-190, miR- 361; most significant: miR-132, miR-10a, and miR-10b | 23; miR-409-5p, miR-656, miR-299-5p, miR-485-5p, miR-424, miR-127, miR-323, miR-339, miR-576, miR-432, miR-433, miR-7, miR-30e-5p, miR-485-3p, miR-379, miR-134, miR-487b, miR-382, miR-486, miR-565, miR-149, miR-550 and miR-503; most significant: miR-409-5p |
Das and Bhattacharyya (2014) [22] (India) | SH-SY5Y | 10 μmol/L for 7 days | 31; miR-9, miR-9*, miR-15b, miR-16, miR-34a, miR-100, miR-124, miR-125b, miR-126, miR-132, miR-134, miR-137, let-7a, miR-432, miR-15a, miR-21, miR-23a, miR-27b, miR-29c, miR-103, miR-125a, miR-128a, miR-140, miR-141, miR-185, miR-326, miR-1320, let-b, let-7e, miR-127 and miR-10a; most significant: miR-432 | 33; miR-17, miR-19a, miR-138, miR-145, miR-146a, miR-148a, miR-150, miR-154, miR-190 miR-194, miR-200a, miR-205, miR-221, miR-299, miR-323, miR-335, miR-30e, miR-133a, miR-133b, miR-142-5p, miR-144, miR-152, miR-185, miR-189, miR-191, miR-193, miR-200c, miR-213, miR-219, miR-296, miR-302a, miR-331 and miR-342; most significant: miR-17 |
Study (reference and country) | Cell type | ATRA treatment | miRNAs upregulated | miRNAs downregulated |
---|---|---|---|---|
Garzon et al. (2007) [23] United States | NB4 | 10−1 μmol /L for 4 days | 9; miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342, and miR-107; most significant: miR-15b |
miR-181b
|
Marchis et al. (2009) [40] Italy | NB4 | 1 μmol/L for 72 h |
miR-342
|
–
|
Gao et al. (2011) [41] China | U937, HL60, NB4 and leukemic fresh cell lines | 1 μmol/L for 72 h | 2; miR-15a and miR-16-1; most significant: miR-15a | – |
Lin et al. (2011) [42] China | NB4, HL60 and K562 | 1 μmol/L for 72 h |
–
|
miR-125b
|
Morris et al. (2013) [43] United States | HL60, NB4, PL21, and THP-1 | 10−3 μmol/L to 1 μmol/L for 21 days | – |
miR-150
|
Zhuang et al. (2014) [44] China | NB4 | 1 μmol/L for 36 h | – |
miR-181a
|
Lin et al. (2015) [45] China | HL60 and NB4 | 3 μ mol/L ATRA for 72 h (HL60) and 2 μmol/L ATRA for 4 days (NB4) |
miR-638
|
–
|
Bräuer-Hartmann et al. (2015) [46] Germany | NB4 | 10−1 μmol/L for 24 h | – | miR-181 cluster (miR-181a, miR-181b, miR-181c and miR-181d); most significant: miR-181a and miR-181b |
Yan et al. (2016) [47] United States | HL60 | 10− 1 and 1 μmol/L for 72 h |
–
| miR-17–92 cluster (miR-17, miR-18a, miR-19b, miR-20a and miR-92); most significant: miR-20a |
Study (reference and country) | Cell type | ATRA treatment | miRNAs upregulated | miRNAs downregulated |
---|---|---|---|---|
Terao et al. (2011) [48] | MCF-7 | 1 μmol/L for 72 h |
miR-21
|
–
|
Khan et al. (2015) [49] Ireland | T47D and SK-BR-3 | 1 and 5 μmol/L for 24 h |
miR-10a
|
–
|
Fisher et al. (2015) [50] Italy | SKBR3, MCF-7, MDA-MB-157 | 10−1 μmol/L (SKBR3) and 1 μmol/L ATRA (MCF-7 and MDA-MB-157) for 36 h | 13; mir-1031; miR-1225-5p1, miR-12681, miR-141, miR-188-5p1, miR-19b1, miR-200c1, miR-211, miR-221, miR-513a-5p1, miR-5751, miR-6421 and miR-6641a | 17; miR-15b12, miR-9612, miR-20312, miR-18312, miR-210-3p123, miR-362-5p12, miR-14912, miR-125a-5p123, miR-193a-5p12, miR-18512, miR-532-5p12, miR-342-3p12, miR-148a1, miR-3751, miR-193a-3p1, miR-2051 and miR-6601a |
Study (reference and country) | Cell type | ATRA treatment | miRNAs upregulated | miRNAs downregulated |
---|---|---|---|---|
Zhu et al. (2015) [3] China | A549 and H1299 | 10 and 100 μmol/L for 24 h (A549); and 100 μmol/L for 72 h (H1299) | 8; miR-594, miR-519b, miR-504, miR-512-3p, miR-363, miR-517a, miR-518a and miR95; most significant: 512-3p | 5; mir-223, miR-196a, miR-369-3p, miR-146a and miR-142-3pa |
Chu et al. (2016) [4] China | H1299 and A549 | 10 and 100 μmol/L for 72 h |
miR-512-5p
|
–
|
Study (reference and country) | Cell type | ATRA treatment | miRNAs upregulated | miRNAs downregulated |
---|---|---|---|---|
Weiss et al. (2009) [51] Germany | PaTu8988-S and PaTu8988- | 1 μmol/L for 72 h |
miR-10a
|
–
|
Xia et al. (2009) [52] China | U343 and U251 | 1 μmol/L for 48 h |
–
|
miR-125b
|
Chen et al. [53] (2014) Taiwan | U87 MG | 10, 20, 40, and 60 μmol/L for 72 h | 13; miR-302b, miR-302a, miR-302d, miR-30a, miR-146a, miR-224, miR-135a, miR-137, miR-212, miR-628-3p, miR-200c, miR-146b-5p and miR-136; most significant: miR-302b | 15; miR-19a, miR-19b, miR-551b, miR-101, miR-301a, miR-199b-5p, miR-455-5p, miR-565, miR-107, miR-216a, miR-32, miR-33a, miR-17-5p, miR-497 and miR-210; most significant: miR-19a |
Chen et al. [54] (2014) China | NT2/D1 | 10 μmol/L for 21 days |
–
|
miR-134
|
Liu et al. [55] (2018) China | HCT116 | 10, 20, 40, and 60 μmol/L for 24 h |
miR-3666
|
–
|